DEBORAH RUSHING: Open Payments
NPI 1922776152 · TROY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$383 in 15 payments from 7 companies in 2025. Trend: 2023 $116 · 2024 $111 · 2025 $383
Food & beverage: $383
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $102 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $92 |
| Otsuka America Pharmaceutical, Inc. | 1 | $74 |
| Corium, LLC | 4 | $40 |
| Tris Pharma Inc | 2 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
Products named: FANAPT, CAPLYTA, REXULTI, Azstarys, AIRSUPRA, TRINTELLIX, Dyanavel XR, Onyda XR.
Industry payments across AL — which companies pay providers there.
